Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €62.88 EUR
Change Today -0.51 / -0.80%
Volume 0.0
ZEG On Other Exchanges
Symbol
Exchange
New York
Stockholm
Mexico
Berlin
As of 2:29 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

the treatment of asthma in both children and adults. Rhinocort (budesonide) is a nasal steroid used as a treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps. Symbicort pMDI (budesonide/formoterol in a pressurised metered-dose inhaler) is a combination of an inhaled corticosteroid and a fast onset, long-acting beta2-agonist used for maintenance treatment of asthma and COPD, including chronic bronchitis and emphysema in the U.S., Australia, and some other markets. Symbicort Turbuhaler (budesonide/formoterol in a dry powder inhaler) is a combination of an inhaled corticosteroid and a fast onset, long-acting beta2-agonist used for the maintenance treatment of asthma and COPD. In asthma, it is also approved for Symbicort Maintenance and Reliever Therapy (Symbicort SMART). Symbicort Turbuhaler is approved in many countries outside the U.S. The company’s Symbicort products improve the health of COPD and asthma patients by providing rapid relief of symptoms and long-term anti-inflammatory control. The company is investing in this brand and is exploring a new indication in mild asthma through the SYGMA trial programme, enhancing its inhaled devices and patient support programmes, and seeking to expand its COPD indications. Through its acquisition of Pearl Therapeutics, Inc. (Pearl Therapeutics) in 2013, the company obtained a Phase IIb LAMA/LABA combination (PT003) and technology that may help develop its Phase II triple FDC (PT010) in one device. Through its strategic transaction with Almirall, S.A. in November 2014, the company acquired rights to the on-market product Eklira Genuair (a LAMA) and to Duaklir Genuair (a combination of aclidinium bromide, a LAMA and formoterol fumarate, a LABA), which was approved in the EU in November 2014. The company also acquired Almirall Sofotech GmbH, an Almirall, S.A. subsidiary focused on the development of inhalation devices. In February 2015, the company announced an agreement with Actavis Plc (Actavis) to acquire the rights to Actavis’s branded respiratory business in the U.S. and Canada, including the rights to develop and commercialise on-market products Tudorza Pressair and Daliresp for COPD. The company would also acquire development rights in the U.S. and Canada for the combination of a fixed dose of aclidinium with formoterol in dry powder inhaler (approved in the EU as Duaklir Genuair). In the Pipeline The company is developing PT003 as a twice daily FDC of two components already approved and marketed in various formulations in many countries – the LAMA glycopyrronium and LABA formoterol (a component of Symbicort). It is the only LAMA/LABA being developed in a pressurised metered-dose inhaler (pMDI). Phase III results for PT003 are expected in 2015. The company is also developing PT010 as a twice daily triple combination LAMA/LABA/ICS (composed of glycopyrronium, formoterol and budesonide, a key component of Symbicort) in a pMDI device for severe COPD. The company is also developing benralizumab, which depletes eosinophils in the blood and airways through a mechanism of action. In August 2014, the company initiated a Phase III programme to evaluate the safety and efficacy of tralokinumab in reducing asthma exacerbations in adults and adolescents with severe, inadequately controlled asthma. Other therapies in development include MEDI9929 is a Phase IIb monoclonal antibody being developed with the company for uncontrolled severe asthma. MEDI9929 binds to thymic stromal lymphopoietin (TSLP), an upstream mediator of Th2 cytokine-induced inflammation, and has the potential to treat non-Th2-mediated asthma, decrease the Th2/Th1 ratio in patients with mild to moderate asthma and reprogramme the allergic phenotype. Brodalumab is an anti-IL-17RA monoclonal antibody being developed with the company for psoriasis and psoriatic arthritis and in Phase IIb for uncontrolled moderate to severe asthma with a high degree of airway reversibility. AZD7624 is an inhaled p38 inhibitor in Phase IIa development for COPD. AZD1419 is an inhaled oligonucleotide TLR9 agonist, has completed Phase I for mild asthma. Infection, Neuroscienc

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €62.88 EUR -0.51

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €88.05 EUR +0.107
Biogen Inc $398.68 USD -2.47
Celgene Corp $116.09 USD -0.11
Eli Lilly & Co $74.30 USD +0.03
Valeant Pharmaceuticals International Inc C$291.88 CAD +0.24
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 68.5x
Price/Sales 3.4x
Price/Book 5.2x
Price/Cash Flow 68.5x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.